<DOC>
	<DOCNO>NCT00988559</DOCNO>
	<brief_summary>This study test efficacy safety different route administration DNA vaccine patient HPV16+ CIN2/3 . Subjects enrol one six treatment group . Subjects enrol first two group receive vaccination intradermally needle-free delivery device . Subjects enrol group 3 4 receive vaccination intramuscularly . Subjects enrol group 5 6 receive vaccine intralesionally .</brief_summary>
	<brief_title>Therapeutic Vaccination Patients With HPV16+ Cervical Intraepithelial Neoplasia ( CIN2/3 )</brief_title>
	<detailed_description>Primary Objectives - To evaluate feasibility toxicity vaccination woman CIN2/3 cause HPV16 - To evaluate effect vaccination histology - To compare immunogenicity three different route administration : intradermal ( ID ) , intramuscular ( IM ) , intralesional ( IL ) . Secondary Objectives : - To evaluate change HPV viral load - To evaluate cellular immune response vaccination - To evaluate humoral immune response vaccination - To evaluate local tissue immune response - To correlate measure immune response clinical response - To correlate measure immune response observe preclinical model</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Carcinoma Situ</mesh_term>
	<mesh_term>Cervical Intraepithelial Neoplasia</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Imiquimod</mesh_term>
	<criteria>patient high grade cervical intraepithelial lesion ( CIN2/3 ) patient whose lesion HPV16+ patient age 18 old patient able give inform consent patient immunocompetent patient pregnant , committed use adequate contraception childbearing age patient minimum hemoglobin level 9 Patients cytologic evidence glandular dysplasia Patients cytologic evidence adenocarcinoma situ Patients pregnant Patients active autoimmune disease Patients take immunosuppressive medication Patients concurrent malignancy except nonmelanoma skin lesion Patients allergy gold . Patients evidence damage skin , mole , scar , tattoo mark propose site ( ) administration might interfere interpretation local skin reaction . History evidence physiciandiagnosed chronic recurrent inflammatory skin disease ( e.g . psoriasis , eczema , atopic dermatitis , hypersensitivity ) propose site administration past 5 year . Patients active autoimmune disease history autoimmune disease require medical treatment systemic immunosuppressant , include : inflammatory bowel disease , systemic vasculitis , scleroderma , psoriasis , multiple sclerosis , hemolytic anemic , immune thrombocytopenia , rheumatoid arthritis , SLE , Sjogren 's syndrome , sarcoidosis . Asthma COPD require systemic corticosteroid routine use inhaled steroid acceptable Patients receive prior chrysotherapy ( administration gold salt treat rheumatoid arthritis ) . Patients history arterial venous thrombosis Patients nonhealed wound . Patients history keloid formation ( ID delivery group ) Patients history hepatitis B persistent infection .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>high grade cervical dysplasia</keyword>
	<keyword>treatment vaccine</keyword>
	<keyword>therapeutic</keyword>
	<keyword>HPV</keyword>
	<keyword>DNA vaccine</keyword>
	<keyword>gene therapy</keyword>
	<keyword>gene gun</keyword>
	<keyword>pre-cancerous</keyword>
</DOC>